JP2023518434A5 - - Google Patents
Info
- Publication number
- JP2023518434A5 JP2023518434A5 JP2022556114A JP2022556114A JP2023518434A5 JP 2023518434 A5 JP2023518434 A5 JP 2023518434A5 JP 2022556114 A JP2022556114 A JP 2022556114A JP 2022556114 A JP2022556114 A JP 2022556114A JP 2023518434 A5 JP2023518434 A5 JP 2023518434A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010197740 | 2020-03-19 | ||
| CN202010197740.4 | 2020-03-19 | ||
| CN202110266549.5 | 2021-03-11 | ||
| CN202110266549 | 2021-03-11 | ||
| PCT/CN2021/081840 WO2021185361A1 (zh) | 2020-03-19 | 2021-03-19 | 白介素2突变体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518434A JP2023518434A (ja) | 2023-05-01 |
| JP2023518434A5 true JP2023518434A5 (https=) | 2024-04-02 |
| JPWO2021185361A5 JPWO2021185361A5 (https=) | 2024-04-02 |
Family
ID=77770497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556114A Pending JP2023518434A (ja) | 2020-03-19 | 2021-03-19 | インターロイキン２変異体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230145766A1 (https=) |
| EP (1) | EP4122952A4 (https=) |
| JP (1) | JP2023518434A (https=) |
| KR (1) | KR20220155316A (https=) |
| CN (1) | CN115698052A (https=) |
| AU (1) | AU2021239225B2 (https=) |
| CA (1) | CA3175717A1 (https=) |
| TW (1) | TWI790573B (https=) |
| WO (1) | WO2021185361A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
| CN114380919B (zh) * | 2020-10-18 | 2024-06-25 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240082364A (ko) * | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
| WO2023169524A1 (zh) * | 2022-03-10 | 2023-09-14 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| CA3259108A1 (en) | 2022-06-16 | 2023-12-21 | Cephalon Llc | Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses |
| CN119365482A (zh) * | 2022-06-17 | 2025-01-24 | 舒泰神（北京）生物制药股份有限公司 | 白介素-2(il-2)突变体及其用途 |
| TW202402784A (zh) * | 2022-07-06 | 2024-01-16 | 中國商科望（上海）生物醫藥科技有限公司 | Il2突變蛋白及其用途 |
| CN118620056A (zh) * | 2023-03-09 | 2024-09-10 | 北京天广实生物技术股份有限公司 | Il-2变体及其用途 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| CN117116336B (zh) * | 2023-10-18 | 2024-01-23 | 深圳新锐基因科技有限公司 | 基于内部原子波动改善蛋白结构柔性弱点的方法和装置 |
| US20250195677A1 (en) * | 2023-12-19 | 2025-06-19 | Cephalon Llc | Uses for attenuated il-2 immunoconjugates |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| JP7637415B2 (ja) * | 2018-06-22 | 2025-02-28 | キュージーン インコーポレイテッド | インターロイキン－２バリアントおよびその使用方法 |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
| KR20240082364A (ko) * | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
-
2021
- 2021-03-19 JP JP2022556114A patent/JP2023518434A/ja active Pending
- 2021-03-19 TW TW110110014A patent/TWI790573B/zh active
- 2021-03-19 AU AU2021239225A patent/AU2021239225B2/en active Active
- 2021-03-19 KR KR1020227034880A patent/KR20220155316A/ko active Pending
- 2021-03-19 US US17/911,893 patent/US20230145766A1/en active Pending
- 2021-03-19 CN CN202180021848.0A patent/CN115698052A/zh active Pending
- 2021-03-19 EP EP21771688.5A patent/EP4122952A4/en active Pending
- 2021-03-19 WO PCT/CN2021/081840 patent/WO2021185361A1/zh not_active Ceased
- 2021-03-19 CA CA3175717A patent/CA3175717A1/en active Pending